Numerator

​

​

​

​

Net income (loss) - before noncontrolling interest

(6,598

)

(12,324

)

(7,662

)

6,300

Net income (loss) attributable to noncontrolling interest

1,214

403

2,218

747

Net income (loss) - as reported, attributable to PAVmed

(5,384

)

(11,921

)

(5,444

)

7,047

​

​

​

​

Series B Convertible Preferred Stock dividends – earned

(95

)

(88

)

(189

)

(175

)

Series C Convertible Preferred Stock dividends - earned

—

(481

)

(145

)

(879

)

Deemed dividend on Series C Convertible Preferred Stock

—

(818

)

(6,689

)

(1,607

)

Net income (loss) attributable to PAVmed common stockholders used in basic EPS calculation

(5,479

)

(13,308

)

(12,467

)

4,386

Fair Value Adjustment for diluted EPS calculation

—

—

—

249

Add back: Series C Convertible Preferred Stock dividends and deemed dividends

—

—

—

2,486

Net income (loss) attributable to PAVmed common stockholders used in dilutive EPS calculation

(5,479

)

(13,308

)

(12,467

)

7,121

​

​

​

​

Denominator

​

​

​

​

Weighted average common shares outstanding, basic

6,269,384

602,822

3,938,037

533,068

Add: Restricted stock awards

—

—

—

10,764

Add: Senior Convertible Note

—

—

—

574,126

Add: Series C Convertible Preferred Stock

—

—

—

691,141

Weighted average common shares outstanding, diluted

6,269,384

602,822

3,938,037

1,809,099

​

​

​

​

Net income (loss) per share (1)

​

​

​

​

Net income (loss) per share attributable to PAVmed common stockholders, basic

(0.87

)

(22.08

)

(3.17

)

8.23

Net income (loss) per share attributable to PAVmed common stockholders, diluted

(0.87

)

(22.08

)

(3.17

)

3.94